<DOC>
	<DOC>NCT00488384</DOC>
	<brief_summary>Acitretin is given to hemodialysis patients who have developed in-situ or invasive squamous cell carcinoma of the skin in increasing doses up to 25 mg daily for one year.</brief_summary>
	<brief_title>Acitretin Plasma Levels Under Hemodialysis</brief_title>
	<detailed_description>Acitretin is given to hemodialysis patients who have developed in-situ or invasive squamous cell carcinoma of the skin in increasing doses up to 25 mg daily for one year. Plasma levels of acitretin will be monitored and influence of hemodialysis on acitretin plasma levels will be determined. Number of in-situ or invasive squamous cell carcinoma of the skin cases will be determined. - Trial with medicinal product</detailed_description>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Acitretin</mesh_term>
	<criteria>Inclusion criteria: Hemodialyis patients with at least one case of insitu or invasive squamous cell carcinoma of the skin Exclusion criteria: Hepatopathy Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Squamous cell carcinoma of the skin under hemodialysis</keyword>
</DOC>